<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946266</url>
  </required_header>
  <id_info>
    <org_study_id>7349</org_study_id>
    <nct_id>NCT04946266</nct_id>
  </id_info>
  <brief_title>Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers</brief_title>
  <acronym>MFI2-PREDICT</acronym>
  <official_title>Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level&#xD;
      with the objective of comparing this expression with tumor tissue. The objective would be to&#xD;
      be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and&#xD;
      for patient follow-up. In addition, correlations will be made between tumor expression of&#xD;
      MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link&#xD;
      between the expression of this long non-coding RNA and the characteristics of the tumor and&#xD;
      of the tumor. tumor microenvironment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of MFI2-AS1</measure>
    <time_frame>36 month</time_frame>
    <description>To assess the link between tumor expression of MFI2-AS1 in patients with localized clear cell kidney carcinoma and the occurrence of relapse</description>
  </primary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical intervention</intervention_name>
    <description>Surgical intervention with collection of tissue material</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with localized kidney tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient&#xD;
&#xD;
          -  Localized kidney tumors&gt; T1a&#xD;
&#xD;
          -  Patient having signed an informed consent&#xD;
&#xD;
          -  Patient affiliated to a health insurance plan&#xD;
&#xD;
          -  Subject having signed a consent form to participate in research and the constitution&#xD;
             of a collection and genetic analyzes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic carcinoma from the outset&#xD;
&#xD;
          -  Contraindication to performing a TAP CT with injection of contrast product&#xD;
&#xD;
          -  Inability to provide informed information about the subject (subject in an emergency&#xD;
             situation, difficulties in understanding, etc.)&#xD;
&#xD;
          -  Subject under legal protection&#xD;
&#xD;
          -  Subject under tutorship or curatorship&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Feeding with milk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TRICARD Thibault</last_name>
    <role>Principal Investigator</role>
    <affiliation>les Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TRICARD Thibault</last_name>
    <phone>+ 33 3.69.55.10.55</phone>
    <email>Thibaut.tricard@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MALOUF Gabriel</last_name>
    <phone>+33 3.88.11.51.41</phone>
    <email>Gabriel.malouf@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>TRICARD Thibault</last_name>
      <phone>+33 03.69.55.10.55</phone>
      <email>Thibaut.tricard@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>TRICARD Thibault</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MALOUF Gabriel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LANG Hervé</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BERGERAT Sébastien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>STORY Fleur</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MUNIER Pierre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

